Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PYGB | P11216 | 8/20 | 0.36 |
| ▸ | PYGL | P06737 | 3/20 | 0.35 |
| ▸ | PYGM | P11217 | 2/20 | 0.35 |
| ▸ | GBA1 | P04062 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CDK1 | P06493 | 1/20 | 0.31 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12459389 | 1.00 | MEN1 (0.38) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL16885871 | 1.00 | MEN1 (0.38) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15959424 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4969695 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL11454071 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL8523079 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL4604138 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15265730 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL15264856 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM | |
| SCHEMBL16547556 | 0.83 | MEN1 (0.51) | MEN1KMT2APYGBPYGLPYGM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318380-B1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | LEXICON PHARMACEUTICALS INC (US) | 2016-08-24 | — | — | EP | disclosed |
| EP-2315765-B1 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-12-19 | — | — | EP | disclosed |
| US-7998994-B2 | Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7998994-B2 | Solid forms of (1R,2S,3R)-1-(2-(isoxazol-3-yl)-1H-imidazol-4-yl)butane-1,2,3,4-tetraol and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2011-08-16 | — | — | US | disclosed |
| US-7968726-B2 | Methods of preparing imidazole-based bicyclic compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| US-7968726-B2 | Methods of preparing imidazole-based bicyclic compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2011-06-28 | — | — | US | disclosed |
| WO-2010008734-A2 | Methods of Preparing Imidazole-Based Bicyclic Compounds | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| WO-2010008733-A2 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-20090318705-A1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318705-A1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318516-A1 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-24 | — | — | US | disclosed |
| US-20090318516-A1 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318705-A1 | METHODS OF PREPARING IMIDAZOLE-BASED BICYCLIC COMPOUNDS | PAICS, TOP2B, CCNI | MEN1 252/4885KMT2A 2913/4885PYGB 1928/4885 |
| US-20090318516-A1 | SOLID FORMS OF (1R,2S,3R)-1-(2-(ISOXAZOL-3-YL)-1H-IMIDAZOL-4-YL)BUTANE-1,2,3,4-TETRAOL AND METHODS OF THEIR USE | TUBAL3, TUBA3C, TUBB3 | MEN1 2823/4885KMT2A 3346/4885PYGB 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.